Details for Patent: 11,129,818

Which drugs does patent 11,129,818 protect, and when does it expire?

Patent 11,129,818 protects ZORYVE and is included in two NDAs.

This patent has forty patent family members in thirteen countries.

Summary for Patent: 11,129,818

Title:	Topical roflumilast formulation having improved delivery and plasma half life
Abstract:	The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
Inventor(s):	David W. Osborne, Bhaskar Chaudhuri, Archie W. THURSTON, JR.
Assignee:	Arcutis Biotherapeutics Inc
Application Number:	US16/778,845
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,129,818
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Dosage form;

United States Drug Patent 11,129,818: Claim Scope, Roflumilast Patent Landscape, and Generic Entry Risk

U.S. Patent No. 11,129,818 claims treatment methods using topical roflumilast compositions containing hexylene glycol, diethylene glycol monoethyl ether, dicetyl phosphate, and ceteth-10 phosphate. Its central commercial theory is that the formulation maintains therapeutically effective roflumilast exposure after one or more missed doses. The patent does not claim roflumilast generally, every topical roflumilast formulation, or the active ingredient as a composition of matter.

The strongest apparent coverage is directed to the specifically recited formulation, particularly the 0.3% roflumilast composition in claim 13, combined with a dosing and missed-dose scenario. Infringement would likely depend on proof of formulation composition, patient use, missed dosing, and the claimed plasma-concentration result.

What does U.S. Patent 11,129,818 protect?

The patent protects method claims with four cumulative elements:

1. A topical roflumilast composition.
2. Four required formulation components:
   • hexylene glycol;
   • diethylene glycol monoethyl ether;
   • dicetyl phosphate; and
   • ceteth-10 phosphate.
3. Administration under a defined dosing regimen.
4. Continued treatment after at least one missed dose, with an asserted therapeutic plasma-exposure benefit.

The claims are not pure formulation claims. A product manufacturer would not necessarily infringe merely by making or selling a cream containing the listed ingredients. The asserted claims require performance of a treatment method.

Claim structure

Claim	Subject matter	Principal limitation
1	Independent method	Add four excipients to roflumilast, administer topically, continue after missed dosing, and maintain therapeutic exposure
2	Dependent method	Two consecutive missed doses
3	Dependent method	Two or more non-consecutive missed doses
4	Dependent method	Dicetyl phosphate and ceteth-10 phosphate supplied in a surfactant blend
5	Dependent method	Blend also contains cetearyl alcohol
6	Dependent method	Surfactant blend is 10% w/w
7	Dependent method	Oil-in-water emulsion, aqueous gel, hydroalcoholic gel, hydrophilic gel, or ointment
8	Dependent method	Additional active agent
9	Dependent method	Topical carriers
10	Independent method	Daily or more frequent topical use, missed dose, no more than two consecutive missed doses, and less than 50% plasma decline
11	Dependent method	Atopic dermatitis
12	Dependent method	Less than 50% plasma decline after three missed days
13	Dependent method	Specific 0.3% roflumilast cream composition
14	Dependent method	Two consecutive missed doses and less than 50% plasma decline

How broad are the independent claims?

Claim 1 is broad in dosage-form terms but narrow in ingredient terms. It covers multiple topical vehicles, including emulsions, gels, and ointments, but requires all four named excipients. The claim also requires a post-missed-dose treatment behavior and a therapeutically effective plasma level.

Claim 10 is narrower in several respects. It requires:

• administration one or more times daily;
• at least one missed dose;
• no more than two consecutive missed doses; and
• a plasma-concentration decrease of less than 50%.

The phrase "one or more times daily" creates an unusual breadth in frequency, because it covers once-daily use and regimens with more frequent administration. The missed-dose limitation materially narrows the claim. A patient who does not miss a dose does not satisfy the express method condition.

Claim 1 versus claim 10

Issue	Claim 1	Claim 10
Missed dosing	At least one missed dose	At least one missed dose
Maximum missed doses	No express maximum in claim 1	No more than two consecutive doses
Plasma result	Therapeutically effective dose level	Less than 50% decrease
Dosing frequency	"On a dosing regimen"	One or more times daily
Atopic dermatitis	Not required	Added by claim 11
Exact formulation	Broad ingredient requirement	Broad ingredient requirement
Commercially specific composition	Claim 13 dependent	Claim 13 dependent

Claim 1 may reach more missed-dose patterns than claim 10, but claim 10 provides a more objective pharmacokinetic limitation. Claim 12 raises a potential internal construction issue because it refers to three days of missed dosing while depending on claim 10, which states "no more than two consecutive doses." The scope of claim 12 may depend on whether "three days" means three calendar days, three missed administrations, or a regimen in which three days elapse while no more than two scheduled doses are missed.

What formulation is recited in claim 13?

Claim 13 identifies the most commercially important formulation in the claim set:

Ingredient	Amount
Roflumilast	0.3% w/w
White petrolatum	10.0% w/w
Isopropyl palmitate	5.0% w/w
Cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate	10.0% w/w
Hexylene glycol	2.0% w/w
Diethylene glycol monoethyl ether	25.0% w/w
Methylparaben	0.2% w/w
Propylparaben	0.05% w/w
Purified water	q.s. to 100%
pH	5.5

The claim text treats cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate as a combined 10% w/w surfactant-blend component. A product with the same qualitative ingredients but materially different concentrations may avoid literal infringement of claim 13 while remaining potentially relevant to claims 1, 4, 5, 7, 9, or 10.

The ingredient combination is commercially significant because diethylene glycol monoethyl ether, also known as Transcutol, and hexylene glycol can function as solvents or penetration-enhancing excipients. Dicetyl phosphate, ceteth-10 phosphate, and cetearyl alcohol can support emulsion structure and product stability. The claims, however, do not expressly require a particular particle size, droplet size, viscosity, release profile, or skin penetration rate.

What is the likely claim-construction risk?

The patent contains several functional and potentially contestable limitations.

"Improving treatment adherence"

Adherence improvement may be interpreted as a treatment objective rather than a separately measurable technical limitation. The claim language ties the objective to continued dosing after a missed dose, but it does not specify a quantitative adherence endpoint.

"Extending the plasma half-life"

The claims refer to extending half-life and maintaining roflumilast exposure, but the supplied claim text does not identify:

• the comparator formulation;
• the baseline half-life;
• the sampling schedule;
• the patient population;
• the assay method;
• the minimum half-life extension; or
• the required statistical threshold.

A validity or noninfringement dispute could focus on whether the specification provides a reproducible test for this limitation.

"Therapeutically effective dose level"

This phrase is potentially vulnerable to indefiniteness arguments if the patent does not identify a concentration range or clinical endpoint. It may also create proof problems in litigation because a plaintiff would need to show that the accused regimen maintained the required plasma level in the relevant patient.

"Plasma concentration decreases by less than 50%"

Claim 10 uses a more measurable threshold, but the reference point remains important. The claim does not state whether the 50% comparison is against:

• the concentration immediately before the missed dose;
• steady-state concentration;
• the concentration after the prior administration;
• the average concentration; or
• a population mean.

The comparator and testing protocol will be central to infringement analysis.

How does the patent compare with ordinary topical roflumilast patents?

The patent has a different claim strategy from a conventional formulation patent.

Patent strategy	Typical protected subject matter	Relevance of Patent 11,129,818
Composition of matter	Roflumilast molecule or salt	Not the apparent focus
Broad formulation	Roflumilast plus defined excipients	Present, but mainly through method claims
Manufacturing process	Mixing, homogenization, temperature, or processing steps	Not apparent from supplied claims
Method of treatment	Disease, concentration, frequency, or patient population	Core strategy
Missed-dose pharmacokinetics	Maintaining exposure after dosing interruption	Distinctive feature
Combination therapy	Roflumilast plus another active agent	Covered through claim 8
Commercial product claim	Exact marketed formula	Most closely approached by claim 13

The patent is strongest against a competitor that uses the same or materially equivalent excipient system and promotes continued treatment after missed doses. It is weaker against a generic or follow-on product that uses a different vehicle, substitutes excipients, or does not rely on the claimed missed-dose pharmacokinetic behavior.

What is the FDA and Orange Book relevance?

Roflumilast is an FDA-approved PDE-4 inhibitor marketed in topical products for inflammatory dermatologic conditions. FDA approvals include topical roflumilast products for plaque psoriasis and seborrheic dermatitis, with later approval of a lower-strength cream for atopic dermatitis. The FDA-approved product and indication determine the relevant abbreviated new drug application pathway and the patent certifications available to a generic applicant. [1]

The Orange Book relevance of Patent 11,129,818 depends on whether the patent is listed for a particular approved roflumilast product and whether its claims are recognized as covering an approved method of use or drug product. A method claim directed to missed-dose pharmacokinetics may face listing questions if it does not correspond clearly to the approved labeling or to an approved indication.

An Orange Book listing would matter because an ANDA applicant could be required to make a Paragraph IV certification and provide notice to the patent holder. A timely infringement action could trigger the statutory 30-month stay under the Hatch-Waxman framework. [2]

The patent number alone does not establish that the patent is listed for every roflumilast product. Orange Book status must be assessed by product, strength, dosage form, and approved labeling. [1]

When does Patent 11,129,818 lose exclusivity?

The patent’s statutory expiration date cannot be determined from the claim text alone. It depends on the earliest effective nonprovisional filing date, any applicable patent-term adjustment, terminal disclaimer, and the patent’s prosecution history. The issue date was in 2021, but patent term generally runs from the relevant filing date rather than from issuance. [3]

A practical exclusivity analysis should separate four dates:

Exclusivity category	What controls the date
Patent expiration	Earliest effective nonprovisional filing date, adjusted by PTA and terminal disclaimer
FDA new chemical entity exclusivity	Applicable only if the product qualifies as an NCE
FDA new clinical investigation exclusivity	Depends on the qualifying approval and statutory exclusivity period
Pediatric exclusivity	Six months if granted and attached to qualifying listed patents or exclusivity

A topical roflumilast product may have multiple patents with different expiration dates. Patent 11,129,818 should therefore be analyzed as one member of the estate rather than as the sole barrier to generic entry.

What Paragraph IV challenges could target this patent?

A generic applicant could challenge the patent on several grounds.

Noninfringement

The applicant could design around one or more required ingredients, avoid the claimed surfactant blend, use a different roflumilast concentration, or omit labeling that instructs treatment after missed doses.

Lack of written description or enablement

The claims cover several dosage forms, additional active agents, and multiple missed-dose patterns. A challenger could argue that the specification does not support the full breadth of those categories or enable the full claimed genus without undue experimentation.

Indefiniteness

Potential targets include:

• "improving treatment adherence";
• "extending the plasma half-life";
• "therapeutically effective dose level";
• "after multiple administrations"; and
• the relationship between "three days of missed dosing" and "no more than two consecutive doses."

Obviousness

A challenger could combine prior art on topical roflumilast, known solvent systems, emulsion surfactants, and standard pharmacokinetic behavior. The patent holder would likely rely on unexpected persistence of exposure after missed dosing and any supporting clinical or pharmacokinetic data.

Anticipation

Anticipation would require a single prior-art reference disclosing all material elements, including the specific excipient combination and missed-dose treatment method. The missed-dose limitations may make anticipation more difficult than a conventional topical-formulation challenge, but they also create questions about whether the limitation reflects a genuine technical distinction or merely a treatment instruction.

What litigation and settlement issues are most material?

The principal litigation questions are likely to be:

1. Whether an accused product contains all four required excipients.
2. Whether the product is used under a regimen covered by the claims.
3. Whether the patent claims require physician or patient awareness of a missed dose.
4. Whether a manufacturer’s labeling induces the claimed method.
5. Whether the plasma-concentration limitation can be proven without testing individual patients.
6. Whether the claims are invalid for indefiniteness, lack of enablement, or obviousness.

A settlement could permit an authorized generic, delayed entry, a license to specified strengths, or a carve-out of atopic dermatitis or other indications. The commercial value of the patent would depend more on its relationship to the approved product label and Orange Book listing than on the patent’s broadest literal language.

How strong is the patent estate for topical roflumilast?

Patent 11,129,818 has targeted rather than universal strength.

Factor	Assessment
Ingredient specificity	Strong against products using the same four-excipient system
Exact commercial formulation	Strongest in claim 13 if the marketed product matches
Method-of-use dependence	Creates proof and inducement issues
Pharmacokinetic limitation	Potentially valuable but dependent on test methodology
Design-around potential	Meaningful through excipient substitution and labeling
Coverage of all topical roflumilast	Limited
Coverage of non-topical roflumilast	None apparent
Biosimilar relevance	None; roflumilast is a small molecule
Generic litigation risk	Highest for an ANDA product matching the formulation and instructions

The estate does not present a biosimilar risk because roflumilast is a small-molecule drug. The relevant challengers are generic manufacturers filing ANDAs, not biosimilar applicants under the Public Health Service Act.

What generic launch scenarios exist?

Scenario 1: Same formulation and same labeling

This presents the highest risk. A generic matching the four excipients, 0.3% strength, topical vehicle, and missed-dose instructions could face a Paragraph IV suit and method-of-use allegations.

Scenario 2: Same active ingredient with excipient substitution

A formulation that removes or replaces hexylene glycol, diethylene glycol monoethyl ether, dicetyl phosphate, or ceteth-10 phosphate may avoid literal infringement. Equivalents arguments would remain possible, depending on the patent language and prosecution history.

Scenario 3: Product with a carved-out label

A generic may omit a patented method from its labeling where FDA regulations permit a valid section viii statement. The viability of that strategy depends on whether the patented use is separable from the approved indication and whether ordinary use still induces the patented method.

Scenario 4: Post-expiration launch

A generic can avoid patent risk by launching after expiration, subject to any separate listed patents, regulatory exclusivity, pediatric extension, litigation settlement, or injunction.

Key Takeaways

• Patent 11,129,818 is principally a method patent, not a broad roflumilast composition patent.
• Claims 1 and 10 require topical roflumilast plus four named excipients.
• Claim 13 is the most product-specific claim and recites a 0.3% roflumilast composition at pH 5.5.
• The patent’s commercial theory is maintenance of roflumilast exposure after missed dosing.
• The most important legal vulnerabilities are claim construction, indefiniteness, enablement, obviousness, and proof of the plasma-concentration limitation.
• Generic risk is highest where the proposed product matches the claimed excipients and labeling.
• Roflumilast is a small molecule, so biosimilar pathways do not apply.
• Orange Book significance depends on product-specific listing status and the relationship between the claims and approved labeling.
• The patent’s exact expiration date requires the patent’s priority, filing, PTA, and terminal-disclaimer data.

FAQs

Does Patent 11,129,818 cover all Zoryve products?

No. The supplied claims require a specific topical excipient combination and treatment conditions. They do not, on their face, cover every roflumilast product, strength, dosage form, or route of administration.

Can a generic avoid the patent by changing one excipient?

Potentially. Replacing a required ingredient may avoid literal infringement, although the patent holder could assert an equivalents theory depending on the claim language, prosecution history, and technical effect of the substituted excipient.

Is claim 13 a product claim?

No. Claim 13 is a dependent method claim. It recites a specific composition, but infringement still requires performance of the treatment method in claim 10.

Does a missed dose have to be disclosed to the physician or patient?

The claim text does not expressly require awareness or disclosure. The relevance of labeling, patient instructions, and induced infringement would depend on claim construction and the evidence concerning how the accused product is used.

Does the patent protect oral roflumilast?

No. The claims supplied require topical administration. Oral roflumilast products do not fall within the literal scope of these claims.

References

1. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Paragraph IV patent certifications. https://www.fda.gov/drugs

3. United States Patent and Trademark Office. (2021). U.S. Patent No. 11,129,818. https://patents.google.com/patent/US11129818B2

4. U.S. Food and Drug Administration. (2024). ZORYVE (roflumilast) prescribing information. https://www.accessdata.fda.gov/drugsatfda/

Drugs Protected by US Patent 11,129,818

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-002	Jul 9, 2024		RX	Yes	Yes	11,129,818					TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-001	Jul 29, 2022		RX	Yes	Yes	11,129,818					TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE OR OLDER
Arcutis	ZORYVE	roflumilast	CREAM;TOPICAL	215985-001	Jul 29, 2022		RX	Yes	Yes	11,129,818					TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 12 YEARS OF AGE AND OLDER. (1)

International Family Members for US Patent 11,129,818

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018282098
Australia	2021214399
Brazil	112019025748